A board-certified hematologic oncology physician, Dr. Matthew Taub oversees patient care at Optimum Oncology Hematology Associates in Pembroke, Florida. Dr. Matthew Taub belongs to organizations that include the American Society of Clinical Oncology (ASCO).One of the world's top medical organizations, ASCO supports physicians and other professionals who serve patients diagnosed with cancer. As part of its mission to ensure quality healthcare offerings, ASCO supplies numerous programs for clinical education, mentorship, and professional development.Opportunities for professional development through ASCO include the Leadership Development Program, which is designed for individuals who have completed medical training in a subspecialty. The year-long program introduces participants to leadership techniques applicable in government, nonprofit, and clinical work.During the year of training, students participate in advocacy in Congress, engage in a variety of interactive sessions, and receive guidance from ASCO mentors.
Florida-based oncologist Matthew Taub serves on the boards of several regional hospitals. In addition, Dr. Matthew Taub is an active member of several professional organizations, including the Florida Medical Association and the American Society of Clinical Oncology (ASCO).Since 1964, ASCO has promoted innovations in cancer care and improvement in patient outcomes by providing education and research opportunities to medical professionals specializing in oncology. ASCO also advocates for policies and regulations that increase access to cancer treatment and high-quality care.One of ASCO’s staunchest platforms is making cancer treatment more affordable. In a policy statement released in 2017, ASCO noted that cancer treatments have become much more effective, but they are not financially accessible to many patients. Treatment costs can run into hundreds of thousands of dollars, causing financial strain that can result in bankruptcy or the forgoing of essential treatment. To combat this, ASCO supports any policy or legislation that aims to lower the cost of cancer drugs, such as negotiating drug prices at the national level.
